Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).

被引：0

作者：

Cavalli, Franco

Rooney, Brendan

Pei, Lixia

Van De Velde, Helgi

Robak, Tadeusz

机构：

[1] Oncol Inst Southern Switzerland, Bellinzona, Switzerland

[2] Janssen Res & Dev, High Wycombe, Bucks, England

[3] Janssen Res & Dev, Raritan, NJ USA

[4] Janssen Res & Dev, Beerse, Belgium

[5] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8500

引用

页数：1

共 50 条

[31] Phase 3 trial of subcutaneous epcoritamab plus R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
Sehn, Laurie Helen
Chamuleau, Martine
Lenz, Georg
Clausen, Michael
Haioun, Corinne
Izutsu, Koji
Davies, Andrew John John
Zhu, Jun
Oki, Toshiko
Szafer-Glusman, Edith
Conlon, Rebekah
Chiou, Hueiyu
Ipe, David
Elliott, Brian
Wu, Jun
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[32] Rituximab plus reduced-dose cyclophosphamide, doxorubicin, vincristine and prednisone (RD R-CHOP) chemotherapy is feasible for very elderly patients (≥80 years) with B-cell lymphoma: analysis of treatment outcome
Shi, Zhan
Tang, Xi
Wang, Jingwen
Shen, Qianwen
Chen, Xi
Chen, Jiayan
Zhuang, Jie
JOURNAL OF CHEMOTHERAPY, 2016, 28 (06) : 487 - 493
[33] PHASE 1B STUDY COMBINING IBRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP) IN PATIENTS WITH CD20-POSITIVE B-CELL NON-HODGKIN LYMPHOMA (NHL)
Younes, A.
Flinn, I.
Berdeja, J.
Friedberg, J.
Alberti, S.
Thieblemont, C.
Morschhauser, F.
Hellemans, P.
Hall, B.
Smit, J.
Skee, D.
de Vries, R.
Todorovic, M.
Khan, I.
Fourneau, N.
Oki, Y.
HAEMATOLOGICA, 2013, 98 : 356 - 356
[34] Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study
Doorduijn, Jeanette K.
Minnema, Monique C.
Kersten, Marie Jose
Lugtenburg, Pieternella J.
Schipperus, Martin R.
Kooy, Marinus van Marwijk
MacKenzie, Marius
Zijlstra, Josee M.
Berenschot, Henriette W.
Schaafsma, M. R.
Chitu, Dana A.
Kluin-Nelemans, Hanneke C.
BLOOD, 2015, 126 (23)
[35] Intensified 14-Day Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (RCHOP14) Compared to R-CHOP (RCHOP21) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT)
Sus, Jose Sandoval
Dalia, Samir
Mhaskar, Rahul
Auseker, Aniket
Chavez, Julio
Sokol, Lubomir
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S276 - S277
[36] Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Hiddemann, W
Dreyling, M
Unterhalt, M
Repp, R
Hermann, S
Haenel, A
Metzner, B
Pott, C
Hartmann, F
Parwaresch, R
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 558S - 558S
[37] Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515
Stopeck, Alison T.
Unger, Joseph M.
Rimsza, Lisa M.
Farnsworth, Brent
LeBlanc, Michael
Iannone, Maria
Fisher, Richard I.
Miller, Thomas P.
BLOOD, 2010, 116 (21) : 260 - 261
[38] One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone
Dimopoulos, Meletios A.
Mateos, Maria-Victoria
Cavo, Michele
Suzuki, Kenshi
Jakubowiak, Andrzej
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Kaplan, Polina
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Chiu, Christopher
Wang, Jianping
Kudva, Anupa
Kobos, Rachel
Wroblewski, Susan
Qi, Ming
San-Miguel, Jesus F.
Blade, Joan
BLOOD, 2018, 132
[39] Elevated High Sensitivity Troponin T (HsTnT) during Front-Line Therapy with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone plus /- Rituximab (CHOP plus /-R) or Cyclophosphamide, Epirubicin, Vincristine and Prednisone plus /- Rituximab (CEpOP plus /-R) Correlates with a Decline in Left Ventricular Ejection Fraction (LVEF) in Patients with Aggressive B-Cell Lymphoma: Results from a Randomized Prospective Clinical Trial NCT00854568
Xue, Kai
Gu, Juan J.
Zhang, Qunling
Liu, Xiaojian
Wang, Jiachen
Luo, Jianfeng
Hernandez-Ilizaliturri, Francisco J.
Fernandez, Stanley F.
Czuczman, Myron S.
Cao, Junning
Hong, Xiaonan
Guo, Ye
BLOOD, 2014, 124 (21)
[40] Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
Davies, Andrew
Caddy, Josh
Mercer, Katy
Saunders, Geoff N.
Stanton, Louise
Collins, Graham P.
Cummin, Thomas E. C.
Schuh, Anna
Ardeshna, Kirit M.
McMillan, Andrew
Radford, John A.
Lewis, David John
Coleman, Adam
Griffiths, Gareth
Burton, Cathy
Barrans, Sharon
Johnson, Peter
BLOOD, 2020, 136

← 1 2 3 4 5 →